Related Experiment Video
Updated: Jan 8, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Navigating the winding road toward precision prostate cancer care
Syed Rahman1, Adith S Arun2, Isaac Yi Kim1
1Department of Urology, Yale School of Medicine, New Haven, CT, United States.
Abstract:
Prostate cancer (PCa) remains the second leading cause of cancer-related mortality among U.S. men, driven in large part by metastatic castration-resistant prostate cancer (mCRPC) despite initial responses to androgen-receptor (AR)-targeted therapies. Over the last two decades, treatment options for mCRPC have significantly expanded to include novel therapeutic modalities that integrate biomarker-guided patient selection. These biomarker-driven therapies have ushered us into the era of "precision oncology" in prostate cancer care, and we highlight key developments. In light of these promising early results, we also review key opportunities and challenges ahead. Additionally, we share a conceptual roadmap to leverage multi-omics molecular data in the era of Artificial Intelligence/Machine Learning (AI/ML) to accelerate progress in prostate cancer precision medicine. Specifically, we discuss how these tools may help facilitate the development of near-patient preclinical models for prostate cancer to better capture key aspects of prostate cancer tumor biology. We also discuss a potential path toward accelerating translation of laboratory discoveries into clinical practice for PCa patients.
Insights
Metastatic castration-resistant prostate cancer (mCRPC) treatments are advancing with precision oncology. Future progress in prostate cancer precision medicine may be accelerated by leveraging multi-omics data and AI/ML.
Area of Science:
- Oncology
- Genomics
- Biotechnology
Background:
- Prostate cancer (PCa) is a leading cause of cancer mortality in U.S. men.
- Metastatic castration-resistant prostate cancer (mCRPC) poses significant treatment challenges despite androgen-receptor (AR)-targeted therapies.
Purpose of the Study:
- To review key developments in biomarker-driven therapies for mCRPC.
- To outline opportunities and challenges in advancing prostate cancer precision medicine.
- To propose a roadmap for utilizing multi-omics data and AI/ML in PCa research.
Main Methods:
- Review of recent advancements in biomarker-guided therapies for mCRPC.
- Analysis of current challenges and future opportunities in prostate cancer precision medicine.
- Conceptual framework for integrating multi-omics data with AI/ML for preclinical model development.
Main Results:
- Biomarker-driven therapies have significantly expanded treatment options for mCRPC.
- Precision oncology is transforming prostate cancer care.
- AI/ML and multi-omics data hold potential for accelerating translational research.
Conclusions:
- Continued advancements in precision oncology are crucial for improving mCRPC outcomes.
- Leveraging multi-omics data and AI/ML can accelerate the development of novel therapies and preclinical models.
- A strategic roadmap is needed to translate laboratory discoveries into clinical practice for mCRPC patients.
